October 16 – Novo Nordisk announced the acquisition of KBP Biosciences for up to 1.3 billion US dollarsTheOcedurenone, useFor treatmentUncontrolled HypertensionCardiovascular and Renal Diseases。Ocedurenone is an oral small-molecule non-steroidal mineralocorticoid receptor antagonist (nsMRA) currently being investigated in the CLARION-CKD Phase 3 trial for patients with uncontrolled hypertension and advanced chronic kidney disease (CKD). Uncontrolled hypertension refers to a condition where a person's blood pressure remains high despite receiving two or more antihypertensive treatments.Novo Nordisk Executive Vice President and Head of Development Martin Holst Lange stated: "Hypertension is a major risk factor for cardiovascular events, heart failure, chronic kidney disease, and premature death. Due to its expected benefit-risk profile,ocedurenone"It has first-class potential in the treatment of uncontrolled hypertension and helps address significant unmet medical needs in patients with cardiovascular disease and chronic kidney disease."
Dr. Zhenhua Huang, founder and chairman of KBP Biosciences, said: "We are delighted to...ocedurenoneThe torch is passed to Novo Nordisk, the global leader in chronic disease management. We believe this transition can unlockocedurenone"to its full potential, benefiting more patients with cardiovascular and kidney diseases worldwide."KBP Biosciences"Chief Development Officer Dr. Fred Yang said, 'This shift is an exciting turning point for KBP in the discovery, research, and development process, as KBP is a young company still establishing itself in the global pharmaceutical industry.'"To date, it has been evaluated in nine clinical trials, including the BLOCK-CKD Phase 2b trial.ocedurenoneA study was conducted. The BLOCK-CKD trial met its primary endpoint in patients with stage 3b/4 CKD and uncontrolled hypertension.ocedurenoneDemonstrated clinically and statistically significant improvement in systolic blood pressure (SBP) from baseline to Day 84. There were no reports of serious hyperkalemia or acute kidney injury associated with ocedurenone in the trial.The Phase 3 CLARION-CKD trial has been initiated in the United States, Europe, and Asia, with the first patient dosed at the end of 2021. It will continue as planned, expecting to enroll more than 600 patients randomized across over 150 sites. Novo Nordisk anticipates initiating additional Phase 3 trials for other cardiovascular and renal disease indications in the coming years, aiming to maximize...ocedurenoneThe full potential.Novo Nordisk's Executive Vice President responsible for commercial strategy and corporate affairs, Camilla Sylvest, stated: "We look forward to adding to our product portfolio."ocedurenone"Because it will complement our current development programs in cardiovascular and chronic kidney diseases. This agreement is closely aligned with our strategic focus of expanding from the core of diabetes to other serious chronic conditions, including through new drug modalities, to help more patients with unmet medical needs."The completion of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions, and is expected to be completed by the end of 2023.The transaction will not affect Novo Nordisk's previously announced 2023 operating profit outlook or its ongoing share repurchase program.Novo Nordisk will fund this acquisition from its financial reserves.
Follow the official account below to see the world!
